Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (TSXV:CLAS.H)

Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

GlobeNewswire March 3, 2021

Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication

GlobeNewswire March 2, 2021

Claritas Pharmaceuticals (TSXV:KLY) to focus on developing R-107 as a therapy for vaccine-resistant COVID-19, Influenza, and other viral infections

John Ballem  March 1, 2021

Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

GlobeNewswire March 1, 2021

IIROC Trading Resumption - KLY.WT.A

Canada NewsWire February 26, 2021

IIROC Trading Resumption - KLY.WT.B

Canada NewsWire February 26, 2021

Kalytera (TSXV:KLY) announces resumption of trading on TSXV

John Ballem  February 26, 2021

Kalytera Announces Resumption of Trading on TSXV

GlobeNewswire February 26, 2021

IIROC Trading Resumption - KLY

Canada NewsWire February 25, 2021

The StockTalk Cannabis Report: Feb 12, 2021

Dave Jackson February 12, 2021

Kalytera Announces Change of Auditor

GlobeNewswire August 31, 2020

Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update

GlobeNewswire August 7, 2020

The StockTalk Cannabis Report: July 31, 2020 - COVID-19 Updates

Dave Jackson July 31, 2020

Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants

GlobeNewswire July 24, 2020

The StockTalk Cannabis Report: July 24, 2020

Dave Jackson July 24, 2020

A Novel Opportunity: A New Coronavirus Treatment

Dave Jackson July 22, 2020

The StockTalk Cannabis Report: July 17, 2020

Dave Jackson July 17, 2020

Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection

GlobeNewswire July 16, 2020

Introducing the Prodrug That’s Anti-COVID-19

Dave Jackson July 15, 2020

Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants

GlobeNewswire July 15, 2020